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Gaucher disease is a multisystem, heterogeneous, autosomal
recessive inherited disease associated with striking variation in
its clinical manifestations, severity and course. It is a pan-
ethnic disease with an estimated 30 000 cases worldwide.1
In type 1 (non-neuronopathic) Gaucher disease, deficiency of
the enzyme glucocerebrosidase results in the accumulation of
glucocerebroside, mainly in the cells of the macrophage system.
There are no discernible neuronopathic manifestations such as
gaze palsies, ataxia, seizures or cognitive disturbances. Type 1
Gaucher disease is associated primarily with parenchymal
disease of the liver, spleen, bone and bone marrow and in
severe cases, the lung. Types 2 and 3 Gaucher disease are
associated with varying degrees of neurological manifestations.
The correlation between clinical phenotype and genotype is not
consistent. Mutations, such as the N370S allele, are known to
have a protective effect against neurological involvement.2 
Typical manifestations in type 1 Gaucher disease include
fatigue, splenomegaly, hepatomegaly and osseous
manifestations (including osteopenia, osteoporosis, avascular
necrosis and lytic lesions of bone).1 Hypersplenism can lead to
anaemia, bleeding and recurrent bacterial infection associated
with neutropenia. Growth retardation in children and delayed
puberty in adolescents are frequently noted.1 Studies of the
natural history of untreated Gaucher disease indicate that the
disease is heterogeneous and shows variable progression in
individual patients.3
Before the development of enzyme replacement therapies,
traditional therapy for Gaucher disease was palliative,
consisting primarily of analgesia, blood transfusion and partial
or total splenectomy, thereby correcting hypersplenism.4 Bone
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Background. Gaucher disease is the most common lysosomal
storage disorder caused by the insufficiency of the lysosomal
enzyme, glucocerebrosidase. This deficiency results in absent
or inefficient conversion of glucocerebroside (a membrane
lipid) to ceramide and glucose. Accumulation of
glucocerebroside occurs primarily in macrophage lysosomes
(i.e. monocytes and macrophages) during phagocytic
degradation of red blood cells. Clinical symptoms arise due
to the displacement of normal cells by lipid-engorged
Gaucher cells. Enzyme replacement therapy (ERT) targets
the macrophage system and has been shown to be successful
in the treatment of type 1 Gaucher disease in adults and
children. ERT (60 U/kg) every 2 weeks decreases and often
reverses organomegaly and haematological complications
and improves quality of life for patients with type 1 Gaucher
disease. The present study describes the course of 9
paediatric patients followed up for 2 - 10 years receiving
low-dose imiglucerase therapy (± 10 U/kg every 2 weeks)
for moderate to severe type 1 Gaucher disease.
Objectives. To evaluate the efficacy of low-dose imiglucerase
therapy in paediatric Gaucher disease.
Subjects and methods.  Data were recorded at a single centre
for 9 paediatric patients. Assessment of response included
serial measurements of haemoglobin (Hb) concentrations,
platelet count, angiotensin-converting enzyme (ACE) and
total acid phosphatase (TAP) levels. Growth was assessed by
serial determinations of body weight and height, plotted
against standard growth charts. Organ size (liver and
spleen) was measured clinically and also radiologically,
where possible.
Results. In this low-dose imiglucerase treatment group: (i)
there was a significant increase in Hb over time — normal
Hb levels were achieved in 7 of the 9 patients after a mean of
3.7 years; (ii) platelet counts increased over time, reaching
normal levels in 7 patients; (iii) there was a significant
decrease in both ACE and TAP over time; (iv) heights and
weights of the subjects increased significantly over time with
treatment, normalising to the expected growth percentiles;
and (v) organ size (liver and spleen) reduced with therapy in
all patients measured.
Conclusion. ERT with low-dose imiglucerase (± 10 U/kg/
fortnight) ameliorates Gaucher disease-associated anaemia
and thrombocytopenia. Low-dose ERT is effective and may
be considered in resource-poor clinical situations when other
alternatives are not available.
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marrow transplantation corrects the enzymatic abnormality in
haematopoietic cells in Gaucher disease. However, this therapy
is dependent on the availability of suitable donors and is
associated with significant morbidity.5
Enzyme replacement therapy (ERT) targets the mannose-
receptor of macrophages and has been highly successful in the
treatment of type 1 Gaucher disease in both adults and
children.6,7 ERT enables definitive correction of the underlying
enzyme deficiency with amelioration, and in some cases,
almost complete reversal of the clinico-pathological effects of
the disease. ERT reduces hepatosplenomegaly, improves
haematological parameters and has a positive effect on health-
related quality of life.8 However, the complex osseous and
pulmonary complications of Gaucher disease may remain
refractory to ERT and complete arrest of bone involvement is
not established in all cases.9,10 Cessation of enzyme therapy or
decreased frequency of treatment may be associated with
recurrence of disease activity with the risk of bone crises and
rapid deterioration in blood parameters of the disease.11
A novel oral treatment that decreases the formation of
glucocerebroside, N-butyldeoxynojirimycin (OGT 918), has
been shown to be safe and effective in adults with Gaucher
disease.12,13 Inhibition of substrate formation lowers the
formation of glycosphingolipids to rates at which the residual
enzyme activity in a given patient can catabolise stored and
incoming lysosomal substrate.12
Current treatment for symptomatic adult and paediatric
patients with Gaucher disease in South Africa is ERT with
imiglucerase, an analogue of the human enzyme beta-
glucocerebrosidase. 
There have been divergent views on the optimal dosage of
imiglucerase. Initial doses of 60 U/kg body weight by
intravenous infusion once every 2 weeks have improved
haematological and visceral parameters within 6 months of
therapy.14 Prolonged treatment over 31/2 years with the 60 U/kg
regimen has a positive effect on bone in both the axial and
appendicular skeleton.9 However, ERT is expensive and several
alternative regimens of ERT have been evaluated.11 Doses as
low as 2.5 U/kg body weight three times a week or 15 U/kg
body weight once every 2 weeks improve haematological
parameters and organomegaly.7,11 These low-dose, high-
frequency regimens are not in widespread use and data are
insufficient to assess efficacy in resolving skeletal
manifestations.11
Recent data from the International Collaborative Gaucher
Group show that most patients treated with ERT achieve
normal haemoglobin levels within 2 years of initiation of
therapy using a dose of 60 U/kg every 2 weeks.15 Platelet
counts increase in patients with or without spleens within the
first 6 months and levels are sustained or increased for up to 5
years. Liver and spleen sizes decrease by 20 - 30% within 1 - 2
years of treatment with reductions of 30 - 40% after 5 years.15
There is a high prevalence of growth retardation in children
and adolescents with type 1 Gaucher disease.14 Treatment with
ERT has been shown to be effective in normalising growth
within 4 - 30 months of treatment.16
In South Africa, because of limited resources, only low-dose
imiglucerase therapy is available. This cohort study is a long-
term follow-up of 9 paediatric patients with type 1 Gaucher
disease undergoing treatment with low-dose imiglucerase (± 10
U/kg every 2 weeks). 
Methods
All paediatric patients from the Johannesburg Hospital
Gaucher Clinic were included in the study. All participants had
type 1 Gaucher disease. There was no control group. Patients
had baseline (pretreatment) data recorded. One patient had
had a partial splenectomy. Follow-up varied from 2 to 10 years.
Seven of the 9 children were monitored for at least 6 years.
Annual data were collected by selecting a data point each year
for each patient. The number of observations per subject over
the period ranged from 3 to 11, with a median of 9. 
Demographic data
The age of subjects at the beginning of the study ranged from 5
to 14 years, with a mean of 8.9 years. Three patients were
female and 6 were male (Table I).
Mutation analysis
Genomic DNA samples were screened for five common
Gaucher disease mutations (N370S, L444P, 84GG, IVS2 + 1,
Table I. Patient data 
Genotype
Allele 1
Patient Gender Ethnic group Allele 2
1 F Caucasian N370S
(Afrikaner) Unidentified
2 M Coloured N370S
V230A*
3 M Caucasian 84GG
(Ashkenazi) R496C
4 M Caucasian N370S
(Afrikaner) R496H
5 M Caucasian N370S
(Afrikaner) P387L*
6 F Caucasian N370S
(Afrikaner) Unidentified
7 M African Delta T36
99G>C*
8 M African Delta T36
Rec Nci1
9 F African Delta T36
Rec Nci1
*Novel mutations.
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R463C), using the single-stranded confirmation polymorphism
(SSCP) method.17
Patient’s DNA carrying an unidentified allele was subjected
to further analysis. Long template PCR, selectively amplifying
the functional GBA gene, was performed and all 11 axons were
subjected to DNA sequencing.18,19
Dosage
Treatment dosage and frequency of administration were
individualised according to patient response. The dosage given
varied from 6 to 13.5 units, with a mean of 10.1 units per
kilogram body weight per fortnight. 
Ethical approval
Ethical approval was granted by the University of the
Witwatersrand Human Research Ethics (Medical) Committee. 
Measurements
Angiotensin-converting enzyme (ACE) is a nonspecific
indicator of lipid storage. Serum ACE activity is generally
elevated in untreated patients with Gaucher disease. Effective
enzyme replacement therapy decreases serum ACE levels.
However, elevated ACE levels alone are not unique indicators
of the clinical severity of Gaucher disease. Tartrate-resistant
acid phosphatase (TRAP) is a metallo-enzyme produced by the
liver. It is one of multiple isoforms of acid phosphatase. High
serum levels of TRAP are seen in untreated cases of Gaucher
disease. Serum TRAP activity may serve as a nonspecific
indicator of lipid storage. While regular monitoring of TRAP is
ideal, consistent measurement of total acid phosphatase (TAP)
activity is usually representative of the same trend.
Chitotriosidase (chito) is a recognised marker of lipid
storage. This test has only recently been introduced in South
Africa. Chito levels are uniquely increased in Gaucher’s
patients. Gaucher cells secrete large amounts of chito and
serum levels of chito correlate directly with the number of
Gaucher cells present. However, 5 - 7% of the population in
South Africa are chito deficient. The dosage of ERT
replacement therapy can be titrated to chito levels — if an
increase in serum chito is seen following initiation of ERT, this
is a likely sign that the individual requires a higher dose of
enzyme. 
In this study, haemoglobin (Hb) values, platelet counts and
ACE levels were serially measured at baseline and at least
annually for all patients. TAP levels were recorded occasionally.
Weight and height were serially recorded for all patients.
Organ sizes (liver and spleen) were measured clinically and
radiologically, where possible.
Definitions
Anaemia was defined based on the Hb level — below the
normal value of 13 g/dl. Thrombocytopenia was defined based
on the platelet count — below the normal value of 370 000
cells/mm3. Normal ranges for ACE activity are 8 - 32 U/l,
while normal TAP levels ranged from 0 to 4.5 U/l.
Outcome measures
Outcome data are presented as serial changes among patients
who had data at baseline and annually for at least 2 years after
initiation of ERT.
Statistical analysis
In the absence of a control group, effectiveness was assessed by
evaluating changes in the selected parameters over time.
Random effects regression models for longitudinal data were
fitted to evaluate changes over time. In these models
adjustment was made for the dosage received and age at
baseline (where these were found to be of some importance).
Gender effects were examined. The rate of change of the
parameter over time was estimated adjusting for these effects.
The use of the random effects longitudinal models enables both
variability between subjects and variability within subjects
over time to be evaluated.20
Results 
Haemoglobin (Fig. 1)
On average the Hb increased significantly by 0.31 units per
year (95% confidence limits 0.23 - 0.39). Normal Hb levels were
achieved and sustained in 7 of the 9 patients after a mean of 3.7
years. Two patients who failed to achieve normal Hb levels had
a lower mean Hb at baseline (8.15 v. 12.24 g/dl) 
(Fig. 1).
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Fig. 1. Haemoglobin levels.
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Leucocytes
The change over time was not significant, viz. an increase of
0.046 units per year (95% confidence limits 0.046 - 0.137).  
Platelets (Fig. 2)
There was strong evidence of a dose-response effect. On
average the platelet count increased by 5.68 for each extra unit
of enzyme, and increased by 3.76 units per year, after adjusting
for dosage. The observed increase in platelet count was not
statistically significant (95% confidence limits 0.27 - 7.79).
In terms of clinical response, only 1 patient did not achieve a
normal platelet count and the normal platelet count was not
sustained in 2 other patients. The 3 subjects who did not
sustain a normal platelet count or who did not achieve a
normal platelet count had lower platelet values at baseline.
These 3 subjects also had a lower white blood cell count, a
higher ACE and a higher TAP at baseline.
Angiotensin-converting enzyme (Fig. 3)
There was strong evidence of a gender effect, with ACE being
on average about 108 units lower in males than females. On
average, the ACE decreased by 14.4 units per year (95%
confidence limits for the decrease are 8.6 - 20.2). The effects of
age at entry and dosage were not significant. All patients
showed a consistent reduction in ACE levels. No patients
achieved normal ACE limits. 
Total acid phosphatase
TAP decreased on average by 3.46 units per year (95%
confidence limits 0.67 - 6.24). Although the TAP levels
decreased in all patients, only 4 patients achieved normal TAP
levels. TAP reductions, however, were not sustained.
Height and weight
Patients in the study grew by on average 5.6 cm per year (95%
confidence limits 5.2 - 6.0 cm). Adjusting for the age at entry,
weight increased significantly over time by an average of 3.92
kg per year (95% confidence limits 3.60 - 4.24 kg/year). 
Reduction of organomegaly
Radiological determinations of hepatic and splenic volume
were not conducted uniformly in all patients. However, all
patients demonstrated a volume decrease within 6 months of
initiating ERT.
Discussion
This report extends the data available on response to ERT in
patients with Gaucher disease. The response rates to low-dose
imiglucerase are important to note, given the cost of ERT.
Analysis of the data from this study has shown that: (i) there
was a significant increase in Hb over time — normal Hb levels
were achieved in 7 patients after 3.85 years (range 1 - 7 years)
of low-dose treatment; (ii) the increase in leucocytes and
platelets over time was not statistically significant; (iii) there
was a significant decrease in both ACE and TAP over time —
however, neither ACE nor TAP levels reached normal limits in
this study; (iv) heights and weights of the subjects increased
significantly over time; and (v) organ size (liver and spleen)
reduced with therapy in all patients.
Although no bone density evaluations were undertaken, no
patient developed a new clinical bone problem.
The interpretation of the data in this study is qualified by
several limitations. The frequency of assessment was hampered
by logistical difficulties of patients in reaching the clinic. The
low-dose regimen and patient monitoring were influenced by
limited resources in the health system. The results of this study
may not be applicable to a specific patient because type 1
Gaucher disease is characterised by substantial clinical
variability and is influenced by genotype. The conclusions that
can be drawn from the study should be tentative given the
small sample size, the range of ages on entry and the fact that
there was no comparator group — in particular no ‘normal
dose’ comparator or a control group.
Conclusion
This study suggests that low-dose ERT with imiglucerase for 
2 - 10 years ameliorates anaemia in paediatric patients with
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Fig. 3. Angiotensin-converting enzyme levels.
Fig. 2. Platelet counts.
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type 1 Gaucher disease. Hb levels normalise after a mean of 3.7
years, as opposed to the 2-year normalisation value achieved
with the 60 U/kg dose. In conclusion, therefore, although the
response to low-dose ERT with imiglucerase may be delayed,
low-dose ERT is effective and should be considered in
resource-poor clinical situations when other alternatives are not
available.
The authors would like to acknowledge Jacqueline van Schoor
from Amayeza Info Services for compilation of this manuscript.
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